Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations clinical trial (NCT06041776). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Befotertinib compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations clinical trial (NCT06041776). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of Befotertinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations clinical trial (NCT06041776). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic if I participate in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations clinical trial (NCT06041776). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations clinical trial (NCT06041776). Contact the study team or your healthcare provider for specific answers.

Question 6

How long will the treatment last, and what are the follow-up procedures?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations clinical trial (NCT06041776). Contact the study team or your healthcare provider for specific answers.

What this study is about